Steven Perrin
Known title: PresidentCIK: 0001824545
Steven Perrin's purchase track record
Steven Perrin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/23/2022 | ELDN | $3K | -6.4% | -15.1% | +2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELDN | ▲ Buy | Grant | 152,353 | $0 | 7/31/2026 | View on chart |
| ELDN | ▼ Sell | Tax Withholding | 72,138 | $244K | 7/31/2026 | View on chart |
| ELDN | ▲ Buy | Open Market | 1,000 | $3K | 11/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart
Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.